Effect of Somatostatin on TSH Levels in Non-Toxic Sporadic Goiter

J. Varea; M. Paredes; G. Garces; C. Ochoa; C. Avila; M. J. Coloma; R. Briones; A. M. Comaru-Schally; A. V. Schally

doi:10.1055/s-2007-1004989

Hormone and Metabolic Research, Inhaltsverzeichnis

Horm Metab Res 1990; 22(12): 627-631
DOI: 10.1055/s-2007-1004989

Clinical

Effect of Somatostatin on TSH Levels in Non-Toxic Sporadic Goiter

J. Varea¹ , M. Paredes¹ , G. Garces¹ , C. Ochoa¹ , C. Avila¹ , M. J. Coloma¹ , R. Briones¹ , A. M. Comaru-Schally² , A. V. Schally²

¹Endocrine Service, Carlos Andrade Marin Hospital, Ecuadorian Social Security Institute, and Ciencia Foundation for the Study of Man and Nature, Quito, Ecuador
²Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center and Tulane University School of Medicine, New Orleans, Louisiana, U. S. A.

Abstract

als PDF herunterladen

Summary

Somatostatin (SS-14; growth hormone-release inhibiting hormone) was infused into eight patients with non-toxic sporadic goiter and into eleven normal control subjects. Each patient was given 150 μg of Somatostatin as an intravenous bolus and 350 μg by infusion over a period of 60 minutes. Somatostatin did not lower the basal TSH levels as compared to the pre-infusion levels in this type of goiter, but produced a decrease in the TSH response to TRH during and after the infusion.

Key words

Goiter - Somatostatin - TRH - TSH

PDF (400 kb)